RLYB Stock — Rallybio Corporation: Cash, EV, Pipeline

Share price

$17.19

Market cap

$91.3M

Cash

$92.8M

Enterprise value

-$1.5M

Balance sheet

Cash	$92.8M
Debt	$0.0M
Net cash	$92.8M
Enterprise value	-$1.5M
Basic shares	5.3M shares
Fully diluted shares	6.3M shares
Fully diluted market cap	$109.1M
Cash per share	$17.52

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading RLYB daily closes…

Loading price history…

Pipeline assets

RLYB116

Phase 1 · Active Modality: small molecule

Target C5

Indications

Complement-related diseases (Phase 1)

Status note Lead program; once-weekly, small-volume subcutaneously injected inhibitor of C5 for complement-related diseases. Completed two Phase 1 studies and a confirmatory PK/PD study in healthy volunteers in 2025 (data reported Q1 2026).

RLYB212

Phase 2 · Terminated

Indications

Fetal and neonatal alloimmune thrombocytopenia (FNAIT) (Phase 2)

Status note Program for the prevention of FNAIT discontinued in April 2025 after Phase 2 PK results did not achieve target concentrations, including the minimum target concentration required for efficacy.

RLYB331

Preclinical · Active Modality: monoclonal antibody

Target MTP-2

Status note Preclinical monoclonal antibody targeting MTP-2. Worldwide exclusive rights obtained in May 2022. Indication not stated in the excerpts.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

No lead program on file for this company.

No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
ADAR1 Capital Management	926,352	+905,817	0.70%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

RLYB — Rallybio Corporation

Balance sheet

Price history

Pipeline assets

Institutional holders